Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

18-12-21	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
18-12-20	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
18-12-20	British shares falter as Fed, oil play Scrooge	RE
18-12-19	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
18-12-18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
18-12-17	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
18-12-07	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
18-12-05	FTSE : falls as growth angst spreads	RE
18-12-05	Growth and trade nerves grind European shares down to two-week low	RE
18-12-05	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
18-12-05	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
18-11-21	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
18-11-21	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

20-05-13	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
20-02-04	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
19-01-07	Shire : Form 8.3 - Takeda Pharmaceutical	PU
19-01-07	Shire : Form 8.3 -	PU
19-01-07	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

19-01-08	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
19-01-07	Les affaires reprennent dans la pharmacie
18-12-21	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18-12-18	Shire : plombé par le déclassement de Takeda
18-12-05	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE	-.--%	-.--%	-	-	0
ELI LILLY AND COMPANY	+1.92%	+3.71%	+50.84%	+165.87%	1,068B
JOHNSON & JOHNSON	+0.69%	+7.11%	+61.50%	+53.85%	641B
ABBVIE INC.	+3.36%	+3.54%	+40.66%	+75.78%	454B
ROCHE HOLDING AG	+2.17%	+10.22%	+41.17%	+36.56%	351B
NOVARTIS AG	+1.46%	+3.87%	+39.70%	+44.49%	299B
ASTRAZENECA PLC	+0.40%	+3.59%	+19.93%	+17.02%	266B
NOVO NORDISK A/S	+2.73%	+3.50%	-25.66%	-36.53%	220B
AMGEN INC.	+3.98%	+6.68%	+29.68%	+65.29%	203B
GILEAD SCIENCES, INC.	+2.52%	+2.53%	+18.18%	+73.79%	162B
Average	+1.98%	+2.76%	+30.67%	+55.13%	407.04B
Weighted average by Cap.	+2.01%	+2.85%	+40.16%	+80.22%

Shire Stock Borsa Italiana

Stocks

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Other Pharmaceuticals

Company Profile